Search
forLearn
5 / 801 resultslearn cannabidiol
learn Kopexil
learn Cyproterone
a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor
learn Spirulina
Research
5 / 1000+ resultsresearch Cosm-nutraceutical nanovesicles for acne treatment: Physicochemical characterization and exploratory clinical experimentation
Vitamin C-based nanovesicles effectively treat acne.
research Integrating herbal components into pharmaceutical formulations for hair woes
Herbal ingredients like aloe vera and hibiscus can help with hair problems like hair loss and dandruff.
research OS PLANOS MUNICIPAIS DE SAÚDE COMO FERRAMENTA DE GESTÃO E PLANEJAMENTO: UM LEVANTAMENTO BIBLIOMÉTRICO A RESPEITO DA PRODUÇÃO ACADÊMICA
The document concludes that Passiflora incarnata may help with anxiety, healthcare workers need mental support, common bacteria cause hospital UTIs, telehealth for heart failure needs research, kids' screen time has increased, pregnant teens are mostly okay with their body image, diagnosing post-surgery tuberculosis is hard, older and severely ill people are more likely to have long COVID symptoms, and psychiatrists should be part of pain management teams.
research EXOSSOMOS E PLASMA RICO EM PLAQUETAS COMO NOVAS TERAPIAS REGENERATIVAS NA ALOPECIA: UMA REVISÃO SISTEMÁTICA DE LITERATURA
Exosome and PRP therapies show promise for treating hair loss but need more research for standardization and safety.
research COMPARAÇÃO ENTRE HPLC E IMUNOTURBIDIMETRIA PARA DOSAGEM DE HEMOGLOBINA GLICADA (A1C) COMO CRITÉRIO DIAGNÓSTICO DE DIABETES MELLITUS
HPLC may detect prediabetes and diabetes earlier than Immunoturbidimetry because it shows higher A1c levels.
Community Join
5 / 118 resultscommunity Cosmo Pharmaceutical (Breezula) fiscal results. Top Line Six month results expected early in the second half of this year.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
community Breezula will hit the market in 2026, Cosmo Pharmaceuticals statement!
Breezula, a hair loss treatment, is expected to cost around $100 a month and is anticipated to be released in 2026. The effectiveness of Breezula is debated, with some suggesting it loses effectiveness over time and others arguing it maintains hair compared to baseline.
community Brief update clascoterone phase 3 - Breezula
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.
community Veradermics is now public with a billion dollar market cap.
Veradermics has a market cap over a billion dollars, comparable to Cosmo pharmaceutical. Users discuss using Kintor's Pirylutamide for hair loss.
community Cosmo Pharma Lists Breezula Phase 3 Trial on ClinicalTrials.gov
A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.